Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

Related Posts

Design of Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT-Echo-AI)

Eusuff S, Kim J, Fatima Z, Yalcinkaya D, Sahashi Y, Sandhu A, Nguyen LH, Ambrosy AP, Cheng PP, Chang ST, Go AS, Ahmad FS, Cheung[...]

A Single-Cell Atlas of Diabetes-Associated Remodeling in the Human Corneal Limbus

Zha D, Wang Y, Shah R, Ebrahimi SM, Poe AJ, Amador C, Inzalaco J, Fealy A, Sawant OB, Kramerov AA, Wang ZP, Ljubimov AV, Saghizadeh[...]

Use of Myocardial Perfusion Imaging to Guide Prognosis and Management in Older Adults: Is There an Age Limit?

Patel KK, Miller RJH, Lemley M, Shanbhag A, Ramirez G, Liang JX, Acampa W, Bateman TM, Dorbala S, Einstein AJ, Hauser MT, Kaufmann PA, Feher[...]